PD-1 and PD-L1 inhibitors

PD-1 and PDL1 inhibitors are emerging front-line treatment for several forms of cancer.

The Business Cocktail

Business Consultant, Oncology based Indications, PD-1 and PD-L1 inhibitors, Pharma Consultant, The Business Cocktail

AstraZeneca dragout Entasis files to fund antibiotic phase 3 for USD 86 Million IPO Massachusetts-based Entasis Therapeutics has spun out...

Read More

Antibody-Drug Conjugate Market Insight

Business Consultant, PD-1 and PD-L1 inhibitors, Uncategorized

DelveInsight, the leading market research and consulting company has added a new report “Antibody Drug Conjugate Insight: Pipeline...

Read More

PD-1 and PD-L1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2015

PD-1 and PD-L1 inhibitors

PD-1and PDL-1 are the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and have an excellent...

Read More
Close